US2018201605A1PendingUtilityA1
Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid
Est. expiryOct 25, 2031(~5.3 yrs left)· nominal 20-yr term from priority
A61P 7/06A61P 37/06A61P 39/00A61P 9/00A61P 43/00A61P 3/10A61P 3/12A61P 3/00A61P 3/04A61P 29/00A61P 17/02A61P 19/02A61P 13/12A61K 31/4184A61K 9/06C07D 403/04A61K 9/0014A61K 47/38
55
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The meglumine salt of 1-(5,6-dichloro-1H-benzo[d]imidazol-2-yl)-1H-pyrazole-4-carboxylic acid (compound (1)) and pharmaceutically acceptable formulations thereof are described. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by prolyl hydroxylase activity.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A formulation comprising the meglumine salt of 1-(5,6-dichloro-1H-benzo[d]imidazol-2-yl)-1H-pyrazole-4-carboxylic acid.
2 . A compound of the formula
in the form of a meglumine salt.
3 . A pharmaceutical composition comprising the compound of claim 2 and a pharmaceutically acceptable excipient.
4 . The formulation of claim 1 , wherein said meglumine salt is in the form of a dihydrate.
5 . A topical ointment comprising the formulation of claim 1 .Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.